Citation: George Frimpong Boafo, Yejiao Shi, Qingqing Xiao, Kosheli Thapar Magar, Makhloufi Zoulikha, Xuyang Xing, Chao Teng, Emmanuel Brobbey, Xiaotong Li, Xiaohong Jiang, Xiaochun Wang, Yi Yang, Samuel Kesse, Wei He. Targeted co-delivery of daunorubicin and cytarabine based on the hyaluronic acid prodrug modified liposomes[J]. Chinese Chemical Letters, ;2022, 33(10): 4600-4604. doi: 10.1016/j.cclet.2022.04.033 shu

Targeted co-delivery of daunorubicin and cytarabine based on the hyaluronic acid prodrug modified liposomes

George Frimpong Boafo ^{a, b, 1} ,
Yejiao Shi ^{c, 1} ,
Qingqing Xiao ^{b, 1} ,
Kosheli Thapar Magar ^b ,
Makhloufi Zoulikha ^b ,
Xuyang Xing ^a ,
Chao Teng ^b ,
Emmanuel Brobbey ^b ,
Xiaotong Li ^b ,
Xiaohong Jiang ^b ,
Xiaochun Wang ^b ,
Yi Yang ^b ,
Samuel Kesse ^c ,
Wei He ^{a, b, *,}

a.
Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China
b.
Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China
c.
Institute of Translation Medicine, Shanghai University, Shanghai 200444, China

weihe@cpu.edu.cn

Received Date: 18 November 2021
Revised Date: 10 April 2022
Accepted Date: 11 April 2022
Available Online: 17 April 2022

Figures(5)

Breast cancer is the most prevalent cancer in women, and it was hard to prevent or diagnose at an early stage. Thus, it is imperative to develop advanced therapeutics for effective treatment. Herein, a targeted daunorubicin (DNR) and cytarabine (ara-C) co-delivery system was developed by modifying the ara-C loaded liposomes (LIP-ara-C) with the hyaluronic acid-DNR (HA-DNR) prodrugs. The co-assembled hybrid nanoparticles (HA-DNR/LIP-ara-C HNPs) exhibited good serum and storage stability with an average diameter of approximately 100 nm. By specifically binding to the CD44 receptors that overexpressed on cancer cells, these HNPs could be uptake via endocytosis and accumulate intracellularly, in which an optimized DNR and ara-C combination at a molar ratio of 1:5 could generate enhanced synergistic effects with reduced dose-related toxicity on cancer cells.
- Breast cancer,
- Daunorubicin,
- Cytarabine,
- Co-delivery,
- Liposomes
1. [1]
  F. Bray, J. Ferlay, I. Soerjomataram, et al., CA-Cancer J. Clin.68 (2018) 394-424. doi: 10.3322/caac.21492
2. [2]
  R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, CA Cancer J. Clin. 72 (2022) 7-33. doi: 10.3322/caac.21708
3. [3]
  A.G. Waks, E.P. Winer, JAMA 321 (2019) 288-300. doi: 10.1001/jama.2018.19323
4. [4]
  H. Joshi, M.F. Press, 22 - Molecular oncology of breast cancer, in: K.I. Bland, E.M. Copeland, V.S. Klimberg, W.J. Gradishar (Eds. ), The Breast, Elsevier, Amsterdam, 2018, pp. 282-307. e5
5. [5]
  M. Piccart-Gebhart, M. Procter, B. Leyland-Jones, et al., N. Engl. J. Med. 353 (2005) 1659-1672. doi: 10.1056/NEJMoa052306
6. [6]
  C. Denkert, C. Liedtke, A. Tutt, G. von Minckwitz, The Lancet 389 (2017) 2430-2442. doi: 10.1016/S0140-6736(16)32454-0
7. [7]
  M. Chavez-MacGregor, E.A. Mittendorf, C.A. Clarke, et al., Oncologist 22 (2017) 1292. doi: 10.1634/theoncologist.2017-0116
8. [8]
  A. Bardia, I.A. Mayer, J.R. Diamond, et al., J. Clin. Oncol. 35 (2017) 2141. doi: 10.1200/JCO.2016.70.8297
9. [9]
  S.M. Swain, J. Baselga, S.B. Kim, et al., N. Engl. J. Med. 372 (2015) 724-734. doi: 10.1056/NEJMoa1413513
10. [10]
  J.F. Robertson, J.P. Lindemann, A. Llombart-Cussac, et al., Breast Cancer Res. Tr. 136 (2012) 503-511. doi: 10.1007/s10549-012-2192-4
11. [11]
  B. Löwenberg, G.J. Ossenkoppele, W. van Putten, et al., New Engl. J. Med. 361 (2009) 1235-1248. doi: 10.1056/NEJMoa0901409
12. [12]
  R.L. Momparler, Exp. Hematol. Oncol. 2 (2013) 1-5. doi: 10.1186/2162-3619-2-1
13. [13]
  J.E. Lancet, G.L. Uy, J.E. Cortes, et al., J. Clin. Oncol. 36 (2018) 2684. doi: 10.1200/jco.2017.77.6112
14. [14]
  W. Wu, Y. Lu, J. Qi, Ther. Deliv. 6 (2015) 1239-1241. doi: 10.4155/tde.15.69
15. [15]
  W. He, X. Xing, X. Wang, et al., Adv. Funct. Mater. 30 (2020) 1910566. doi: 10.1002/adfm.201910566
16. [16]
  R. Quere, S. Andradottir, A. Brun, et al., Leukemia 25 (2011) 515-526. doi: 10.1038/leu.2010.281
17. [17]
  W. Li, C. Zhou, Y. Fu, et al., Acta Pharma. Sin. B 10 (2020) 693-710. doi: 10.1016/j.apsb.2019.07.003
18. [18]
  Y. Luo, G.D. Prestwich, Bioconjugate Chem. 10 (1999) 755-763. doi: 10.1021/bc9900338
19. [19]
  W. Liu, D. Li, Z. Dong, et al., Int. J. Pharm. 587 (2020) 119682. doi: 10.1016/j.ijpharm.2020.119682
20. [20]
  Y. Lv, C. Xu, X. Zhao, et al., ACS Nano 12 (2018) 1519-1536. doi: 10.1021/acsnano.7b08051
21. [21]
  B.A. Carneiro, W.S. El-Deiry, Nat. Rev. Clin. Oncol. 17 (2020) 395-417. doi: 10.1038/s41571-020-0341-y
22. [22]
  A. Arouri, A.H. Hansen, T.E. Rasmussen, O.G. Mouritsen, Curr. Opin. Colloid Interface Sci. 18 (2013) 419-431. doi: 10.1016/j.cocis.2013.06.001
1. [1]
  Jia Wang , Yunxiu Fan , Shilin Xu , Zhouxue Wu , Tian Hu , Yun Lu , Yue Li , Kang Xiong , Hongjun Deng , Jingrong Huang , Bo Yang , Shaozhi Fu . Self-propelled biomotors co-deliver doxorubicin liposomes and aPD-1 antibody to fight breast cancer. Chinese Chemical Letters, 2026, 37(2): 111607-. doi: 10.1016/j.cclet.2025.111607
2. [2]
  Yunjie Dang , Yanru Feng , Xiao Chen , Chaoxing He , Shujie Wei , Dingyang Liu , Jinlong Qi , Huaxing Zhang , Shaokun Yang , Zhiyun Niu , Bai Xiang . Development of a multi-level pH-responsive lipid nanoplatform for efficient co-delivery of siRNA and small-molecule drugs in tumor treatment. Chinese Chemical Letters, 2024, 35(12): 109660-. doi: 10.1016/j.cclet.2024.109660
3. [3]
  Yeqi Huang , Yue Gao , Yuxin Lin , Yihao Li , Si Xiong , Xia Guo , Chuanbin Wu , Xin Pan , Wenhao Wang , Ziyu Zhao , Zhengwei Huang . “Connect” or “drag”? The impact of physiologically relevant inorganic ion pairs on the protein corona adsorption onto liposomes. Chinese Chemical Letters, 2026, 37(2): 111014-. doi: 10.1016/j.cclet.2025.111014
4. [4]
  Lijuan Liu , Zhihao Zhao , Feiwan Zou , Wukun Liu , Yunlong Lu . Advances in combination therapy for the treatment of estrogen receptor positive breast cancer. Chinese Chemical Letters, 2025, 36(10): 111451-. doi: 10.1016/j.cclet.2025.111451
5. [5]
  Keqiang Shi , Xiujuan Hong , Dongyan Xu , Tao Pan , Huiwen Wang , Hongru Feng , Cheng Guo , Yuanjiang Pan . Analysis of RNA modifications in peripheral white blood cells from breast cancer patients by mass spectrometry. Chinese Chemical Letters, 2025, 36(3): 110079-. doi: 10.1016/j.cclet.2024.110079
6. [6]
  Xinyue Han , Yunhan Yang , Jiayin Lu , Yuxiang Lin , Dongxue Zhang , Ling Lin , Liang Qiao . Efficient serum lipids profiling by TiO₂-dopamin-assisted MALDI-TOF MS for breast cancer detection. Chinese Chemical Letters, 2025, 36(5): 110183-. doi: 10.1016/j.cclet.2024.110183
7. [7]
  Lulu He , Le Wang , Zhen He , Yiqian Yang , Cheng Heng Pang , Aiguo Wu , Bencan Tang , Juan Li . An imine-linked covalent organic framework with intrinsic photo-induced mitochondrial regulation for breast cancer therapy. Chinese Chemical Letters, 2025, 36(9): 110717-. doi: 10.1016/j.cclet.2024.110717
8. [8]
  Haozhi Lei , Qian Xia , Xiqiu Wang , Yang Sun , Weihong Tan . Simulation of immune signal transduction through DNA strand displacement. Chinese Chemical Letters, 2025, 36(12): 110941-. doi: 10.1016/j.cclet.2025.110941
9. [9]
  Hongyi Huang , Siyao Che , Wenjie Zhou , Yunchu Zhang , Weiling Zhuo , Xijing Yang , Songping Zheng , Jiagang Liu , Xiang Gao . Apatinib potentiates doxorubicin with cRGD-functionalized pH-sensitive micelles against glioma. Chinese Chemical Letters, 2025, 36(5): 110084-. doi: 10.1016/j.cclet.2024.110084
10. [10]
  Chenshi Lin , Chao Teng , Bingbing Li , Wei He . Anti-inflammatory drug-assisted microRNA gene therapy for effectively improving pulmonary hemodynamics. Chinese Chemical Letters, 2025, 36(7): 110450-. doi: 10.1016/j.cclet.2024.110450
11. [11]
  Jiangshan Xu , Weifei Zhang , Zhengwen Cai , Yong Li , Long Bai , Shaojingya Gao , Qiang Sun , Yunfeng Lin . Tetrahedron DNA nanostructure/iron-based nanomaterials for combined tumor therapy. Chinese Chemical Letters, 2024, 35(11): 109620-. doi: 10.1016/j.cclet.2024.109620
12. [12]
  Jialin Xie , Qing Feng , Zhen Li , Jinyi Yang , Min Liu , Wei Qi . Life’s Guardian Angel: Progesterone. University Chemistry, 2024, 39(10): 416-419. doi: 10.12461/PKU.DXHX202403068
13. [13]
  Li Fu , Ziye Su , Shuyang Wu , Yanfen Cheng , Chuan Hu , Jinming Zhang . Redox-responsive hyaluronic acid-celastrol prodrug micelles with glycyrrhetinic acid co-delivery for tumor combination therapy. Chinese Chemical Letters, 2025, 36(5): 110227-. doi: 10.1016/j.cclet.2024.110227
14. [14]
  Xiying Wu , Anze Liu , Yuzhong Yan , Ying Lu , Huan Wang . Folic acid ameliorates the immunogenicity of PEGylated liposomes. Chinese Chemical Letters, 2025, 36(6): 110285-. doi: 10.1016/j.cclet.2024.110285
15. [15]
  Lin Li , Bingjun Sun , Jin Sun , Lin Chen , Zhonggui He . Binary prodrug nanoassemblies combining chemotherapy and ferroptosis activation for efficient triple-negative breast cancer therapy. Chinese Chemical Letters, 2024, 35(10): 109538-. doi: 10.1016/j.cclet.2024.109538
16. [16]
  Linping Zhao , Jianqiao Li , Guangmiao Chen , Chuyu Huang , Hangyu Zhou , Rongrong Zheng , Youqin Xu , Xueyan Jiang , Xiaohui Chen , Shiying Li . Cuproptosis amplifier of copper-telaglenastat coordinate to trigger cell ferroptosis for synergistic breast cancer suppression. Chinese Chemical Letters, 2026, 37(1): 110959-. doi: 10.1016/j.cclet.2025.110959
17. [17]
  Shengyi Gong , Guoqiang Feng . Visible light-triggered NIR ratiometric fluorescent metal-free CO-releasing molecule for self-monitoring of CO delivery and effective cancer therapy. Chinese Chemical Letters, 2025, 36(7): 110409-. doi: 10.1016/j.cclet.2024.110409
18. [18]
  Yizhi Ge , Jiahui Zou , Hui Liu , Wei He , Huanfeng Zhu . Cisplatin-polyphenol complex liposomes reduce chemotherapy toxicity. Chinese Chemical Letters, 2026, 37(1): 111450-. doi: 10.1016/j.cclet.2025.111450
19. [19]
  Honghao Sun , Huimin Zhao , Ronghui Yin , Chenxi Zhou , Ming Wu , Yueyang Deng , Zhanwei Zhou , Minjie Sun . Injectable hydrogel-based tumor vaccine with fibrotic tumor immune microenvironment remodeling to prevent breast cancer postoperative recurrence and metastases. Chinese Chemical Letters, 2025, 36(5): 110067-. doi: 10.1016/j.cclet.2024.110067
20. [20]
  Peng Gao , Yuanyuan Chen , Qianlin He , Xue Liu , Echuan Tan , Zhiqiang Yu , Hui Wang . Highly efficient adoptive cell therapy of metastatic triple negative breast cancer with bioactive covalent organic framework-engineered macrophages. Chinese Chemical Letters, 2025, 36(8): 110585-. doi: 10.1016/j.cclet.2024.110585

Get Citation

PDF

XML

Metrics

PDF Downloads(14)
Abstract views(1614)
HTML views(125)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142